The programme is focused on external quality assessment of testing of mutations of clinically most important genes
relevant to anti-EGFR therapy in colorectal carcinoma - KRAS, NRAS, BRAF. Participants are expected to identify and describe
mutations, they can choose any combination of KRAS, NRAS, BRAF testing.
Complete description you can find in the EQA Plan 2021 (namely pages 1 and 30).
Short description is available in the CRC 2021 flyer.
European Society of Pathology Quality Assurance Foundation
Barastraat 6, 1070 Brussels, Belgium
|SEKK s.r.o., EHK Division|
Za Pasáží 1609, 530 02 Pardubice, Czech Republic
|Accreditation:||Certificate of accreditation|
The laboratories from all countries are welcome to participate in CRC programme.
These examples will give you a good insight.
|Public part of the evaluation|
(EQA round CRC1/20)
|Private part of the evaluation|
(anonymised examples from EQA round CRC1/20)
Confirmation of attendance
|Certificate of approval||Result sheet|
To view the last assessed EQA round (CRC1/20) please click here.
Last update: 5.1.2021